President Trump has signed Phase I of a much anticipated multi-part trade agreement between the United States and China with provisions that will aid the branded pharmaceutical industry. One of the main goals of the agreement...more
1/23/2020
/ China ,
Counterfeit Drugs ,
Criminal Liability ,
Dispute Resolution ,
Generic Drugs ,
Hatch-Waxman ,
Injunctive Relief ,
Intellectual Property Protection ,
Patent Infringement ,
Patents ,
Pharmaceutical Industry ,
Prescription Drugs ,
Trade Agreements ,
Trade Secrets ,
Trump Administration ,
US Trade Policies